BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2519 related articles for article (PubMed ID: 34645167)

  • 21. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel prognostic score for outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with metachronous peritoneal carcinomatosis.
    Chin KM; Tan GHC; Chia CS; Ong JCA; Teo MCC
    ANZ J Surg; 2020 Oct; 90(10):1958-1964. PubMed ID: 32159299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
    Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients.
    Mercier F; Passot G; Villeneuve L; Levine EA; Yonemura Y; Goéré D; Sugarbaker PH; Marolho C; Bartlett DL; Glehen O;
    Ann Surg Oncol; 2018 Apr; 25(4):1094-1100. PubMed ID: 29238881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: analysis of short- and long-term outcomes.
    Rosa F; Galiandro F; Ricci R; Di Miceli D; Quero G; Fiorillo C; Cina C; Alfieri S
    Langenbecks Arch Surg; 2021 Dec; 406(8):2797-2805. PubMed ID: 34661754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
    Teo MC; Ching Tan GH; Lim C; Chia CS; Tham CK; Soo KC
    Asian J Surg; 2015 Apr; 38(2):65-73. PubMed ID: 25059814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [CYTOREDUCTIVE SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY FOR PERITONEAL CARCINOMATOSIS OF COLORECTAL ORIGIN - FIRST 100 CASES].
    Berger Y; Jacoby H; Zager Y; Lebedyev A; Gutman M; Hoffman A
    Harefuah; 2019 Apr; 158(4):227-232. PubMed ID: 31032553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peritoneal carcinomatosis in colorectal cancer: Defining predictive factors for successful cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A pilot study.
    Mahmoud AM; Ismail YM; Hussien A; Debaky Y; Ahmed IS; Mikhael HSW; Moneer M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):143-150. PubMed ID: 30472198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis.
    Lin EK; Hsieh MC; Chen CH; Lu YJ; Wu SY
    Medicine (Baltimore); 2016 Dec; 95(52):e5522. PubMed ID: 28033247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy in Primary Advanced Ovarian Cancer: The First Reported Pilot Experience from Saudi Arabia.
    Abu-Zaid A; Alomar O; Alsabban M; Salem H; Al-Badawi IA
    Gulf J Oncolog; 2020 Sep; 1(34):19-25. PubMed ID: 33431358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study.
    Solaini L; D'Acapito F; Passardi A; Framarini M; Tauceri F; Di Pietrantonio D; Frassineti GL; Casadei Gardini A; Cucchetti A; Cavaliere D; Ercolani G
    World J Surg Oncol; 2019 Mar; 17(1):58. PubMed ID: 30917826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat peritoneal carcinomatosis from gastric cancer: a clinical study of 110 patients].
    Ji ZH; Li XB; Liu G; Yu Y; Lin YL; Zhang YB; Li Y
    Zhonghua Yi Xue Za Zhi; 2018 Oct; 98(38):3079-3083. PubMed ID: 30392267
    [No Abstract]   [Full Text] [Related]  

  • 34. Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis.
    Narasimhan V; Tan S; Kong J; Pham T; Michael M; Ramsay R; Warrier S; Heriot A
    Colorectal Dis; 2020 Nov; 22(11):1482-1495. PubMed ID: 32027455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China.
    Su YD; Yang ZR; Li XB; Yu Y; Du XM; Li Y
    Int J Hyperthermia; 2022; 39(1):706-712. PubMed ID: 35485308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
    Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of the immuno-peritoneal cancer index in peritoneal metastatic patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Yildirim Y; Sokmen S; Cevlik AD; Bisgin T; Manoglu B; Obuz F
    Langenbecks Arch Surg; 2023 May; 408(1):182. PubMed ID: 37148400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peritoneal carcinomatosis from unusual cancer origins: Is there a role for hyperthermic intraperitoneal chemotherapy?
    Honoré C; Goéré D; Macovei R; Colace L; Benhaim L; Elias D
    J Visc Surg; 2016 Apr; 153(2):101-7. PubMed ID: 26698380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
    Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
    World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma.
    Mercier F; Jeremie G; Alyami M; Delphine V; Vahan K; Pascal R; Sylvie I; Guillaume P; Olivier G
    Surg Endosc; 2020 Nov; 34(11):4916-4923. PubMed ID: 31792692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 126.